HAE
Haemonetics Corp
Haemonetics Corp historical holders
total: 3
Ariel Appreciation Fund Haemonetics Corp transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
John W. Rogers Jr. has been an institutional investor in Haemonetics Corp (HAE) since 2026 Q2. According to 2026 Q2 report, John W. Rogers Jr. holds 195,810 shares with a market value of roughly $14.69M representing 1.53% of their equity portfolio. The fund/company first acquired HAE in 2026 Q2, initially purchasing 195,810 shares.
Does John W. Rogers Jr. still hold HAE?
Yes, John W. Rogers Jr. continues to hold Haemonetics Corp (HAE). According to their 2026 Q2 report, they maintain a position of 195,810 shares valued at approximately $14.69M, representing 1.53% of their equity portfolio.
When did John W. Rogers Jr. first invest in HAE?
John W. Rogers Jr. first invested in Haemonetics Corp (HAE) in 2026 Q2 at the reported quarter-end price of $75.00 per share, acquiring 195,810 shares in their initial purchase.
What is John W. Rogers Jr.'s average cost basis for HAE?
Based on historical transaction data, John W. Rogers Jr.'s estimated cost basis for Haemonetics Corp (HAE) is approximately $75.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $75.00
HAE transactions history by Ariel Appreciation Fund
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.53%
|
195,810
|
$75.00
|
$14,685,750
|
new
|
+1.53%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.